Study of Ceroluplasmin and some immunological parameters in renal failure and iron deficiency anemia patients
Article Sidebar
Main Article Content
Abstract
The current study included 130 people over a period of research from October 2015 to May 2016 who have renal failure, iron deficiency anemia. Samples were studied divided in three groups: the first group: included 50 patients (62-20 years) with renal failure, and the second group: included 50 patients (34-5 years) from anemic iron deficiency, in addition to the 30 healthy persons (18-54 years) represented a group of healthy control. The present study aimed to find out the dynamic effect of the ceroluplasmin and its role in anemia among patients with iron deficiency anemia as well as anemia in patients with renal failure, in addition to the effect of some of the immune status in patients indicators which (IL-4), (IL-6) and (IL-10), The study concludes the following results: The results showed the presence of high-altitude CP in patients groups and for both males and females when compared with the control group. significant rise in the level of and IL- 4, IL-6 and IL- 10 for patients with renal failure, iron deficiency anemia and thalassemia, and for both males and females
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Wolf, T.; Kotun, J. and Meador-Woodruff, J. (2006). "Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia"; Schizophr. Res. 86(13):167–71.
2. Sirajwala, H.; Dabhi, A.; Malukar, N.; Bhalgami, R. and Pandya, T. (2007). Serum Ceruloplasmin Level as an Extracellular Antioxidant in Acute Myocardial Infarction; J. Indian Acad. Clin. Med. 8:135-138.
3. Lutsenko, S.; Gupta, A.; Burkhead, J. and Zuzel, V. (2008). "Cellular multitasking: the dual role of human Cu-ATPases in cofactor delivery and intracellular copper balance"; Arch. Biochem. Biophys. 476 (1):22–32.
4. Kono, S. (2013). Aceruloplasminemia: An update; Int. Rev. Neurobiol. 110:125–151.
5. Ramos, D.; Mar, D.; Ishida, M.; Vargas, R.; Gaite, M.; Montgomery, A. and Linder, M. (2016). Mechanism of Copper Uptake from Blood Plasma Ceruloplasmin by Mammalian Cells. PLoS ONE. 11(3):16.
6. Gaware, V.; Kotade, K.; Dhamak, K. and Somawanshi, S. (2010). Ceruloplasmin its role and significance: a review. Int. J. Biol. Res. 1:153-162.
7. Ozaktay, A.; Kallakuri, S. and Takebayashi, T. (2006). Effects of interleukin-1 beta, interleukin-6, and tumor necrosis factor on sensitivity of dorsal root ganglion and peripheral receptive fields in rats. Eur. Spine J.; 1–9.
8. Andrews N. (2004). Anemia of inflammation: the cytokine-hepcidin link. J. Clin. Inves. 113(9 ): 1251 – 1253.
9. Sunderman F. and Nomato, S.(1970). Measurment of serum ceruloplasmin by its para-phonylendiamine oxidase activity . J. Clin. Chem. 6(11): 903-910.
10. Steel, R. and Torries, J. (1980). Principle and Procedures of Statistics :A Biochemical Approach. 2nd edition, McGraw-Hill Book Company Inc., New York, USA.
11. Panichi, V. Rosati, A. Bigazzi, R. Paoletti S. and Mantuano E. (2011). Anaemia and resistance to erythropoiesis -stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol. Dial. Transplant. 26: 2641-2648
12. Awadallah , S.; Atoum, M.; Nimer, N. and saleh, S. (2012). Ischemia modified albumin: An oxidative stress marker in β-Thalassemia major. Clinca. Chimica. Acta. 413: 907-910.
13. Balne, N. and Rao, C. (2012). Role of XmnI restriction site polymorphism and JAK2 gene mutation in β-Thalassemia. Int. Res. J. Biological Sci. 21: 41-45.
14. Sheeba, V. Arun P. and Swarnalatha. P. (2016). Correlation of hemoglobin with creatinine clearance, antioxidant status, lipid peroxidation and ceruloplasmin in patients with chronic kidney disease. Int. J. Res. Med. Sci.; 4(10): 4487-4492.
15. Roxborough, H.; Mercer, C.; McMaster, D.; Maxwell, A. and Young, I. (2000). The Ferroxidase Activity of Caeruloplasmin Is Reduced in Haemodialysis Patients. Nephron. 84:211 -217.
16. Ashok, K.; Sajida, M. and Joseph, S. (2010). Plasma ceruloplasmin in chronic renal failure patients undergoing haemodialysis. Journal of Clinical and Diagnostic Research.;41:2058–2060.
17. Farheen, M. Jayashree G. and Asmita P. (2016). Pre and Post levels of serum Ferritin and Ceruloplasmin in Chronic Kidney Disease Patients on Hemodialysis . Indian Journal of Basic and Applied Medical Research; 5(4): 584-587.
18. AL –Karawyi, M. ; Mousa, T. and Al-Salih, R . (2013). Study of serum oxidant-antioxidants status in patients with chronic renal failure. International Journal of Research in Pharmaceutical and Biomedical Sciences ;4(1):385 – 393.
19. Chakraborty ,D. and Bhattacharyya, M. (2001): Antioxidant defense status of red blood cells of patients with b-thalassemia and E beta-thalassemia. Clin. Chim. Acta.; 305: 123– 9.
20. Koren, A.; Fink, D.; Admoni, O.; Tennenbaum - Rakover, Y. and Levin, C. (2010). Non-transferrin bound labile plasma iron and iron overload in Sickle Cell Disease: a comparative study between Sickle Cell Disease and b thalassemic patients. Eur. J. Haematol. 84:72–8.
21. Kohgo, Y.; Ikuta, K.; Ohtake, T.; Torimoto, Y. and Kato, J. (2008). Body iron metabolism and pathophysiology of iron overload. Int J. Hemato. 88 :7-15.
22. Amdur, R.; Mukherjee, M.; Go, A.; Barrows, R.; Ramezani, A.; Shoji, J.; Reilly, M.; Gnanaraj, J.; Deo, R.; Roas, S.; Keane, M. and Master, S. ( 2016). Interleukin-6 is a risk factor for atrial fibrillation in chronic kidney disease: findings from the CRIC Study. PLoS One.;11:36 – 47.
23. Vianna, H.; Soares, C.; Tavares, M.;Teixeira, M. and Silva, A. (2011) . Inflammation in chronic kidney diseases: the role of cytokines. Braz. J. Nephrol. 33:351–364.
24. Imig, J. and Ryan, M. (2013). Immune and Inflammatory Role in Renal Disease. Compr. Physiol.; 3(2): 957–976.
25. Vento, S.; Cainelli, F. and Cesario, F. (2006). Infections and thalassemia. Lancet Infect Dis. 6:226–233 .
26. Abo Shanab, M.; El-Desouky, A.; Kholoussi, N.; El-Kamah, G. and Fahmi, A. (2015). Evaluation of neopterin as a prognostic factor in patients with beta-thalassemia, in comparison with cytokines and immunoglobulins Archives of Hillenic Medicine; 32(1):60 -65.
27. Hashad, R.; Hamed, N. and El Gharabawy, M. (2013). Interleukins 12 and 13 levels among beta-thalassaemia major patients. East Mediterr. Health J. 19(2):181-5.
28. Nakagawa, H.; Tamura, T.; Mitsuda, Y.; Goto, Y.; Kamiya, Y.; Kondo, T.; Wakai, K. and Hamajima, N. (2014).Inverse correlation between serum interleukin-6 and iron levels among Japanese adults: a cross-sectional study . BMC Hematology .14:6 – 13 .
29. Mu, W.; Ouyang, X.; Agarwal, A.; Zhang, L.; Long, D. and Cruz, P. (2005). IL-10 Suppresses Chemokines, Inflammation, and Fibrosis in a Model of Chronic Renal Disease. J. Am. Soc. Nephrol. 16:3651–366.